Combination Therapy...
 
Notifications
Clear all

Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

1 Posts
1 Users
0 Likes
186 Views
johan
(@j)
Joined: 4 years ago
Posts: 1199
Topic starter  

Pharmacologic inhibition with dual small molecule inhibitor therapy targeting this pair of key nodes further demonstrated enhanced antileukemia efficacy of combining the BCL-2 inhibitor venetoclax with the tyrosine kinase inhibitors ruxolitinib or dasatinib in vitro in human Ph-like ALL cell lines and in vivo in multiple childhood Ph-like ALL patient-derived xenograft models. Consistent with network controllability theory, co-inhibitor treatment also shifted the transcriptomic state of Ph-like ALL cells to become less like kinase-activated BCR-ABL1-rearranged (Ph+) B-ALL and more similar to prognostically favorable childhood B-ALL subtypes.

https://pubmed.ncbi.nlm.nih.gov/34210682/


   
Quote
Share: